Who is sponsoring NCT01476930?

NCT01476930 is sponsored by Birjand University of Medical Sciences.

What condition does NCT01476930 study?

NCT01476930 studies Migraine Headache.

What drugs are being tested in NCT01476930?

Interventions: cupping and serkangabin syrup, conventional migraine drug treatment.

What is the status of NCT01476930?

NCT01476930 is currently COMPLETED.

Last reviewed 2014-11-20 · How we verify

Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial

NCT01476930 Phase 4 COMPLETED

Migraine is the most common recurrent headache. Current therapy of migraine headache consists of multiple drug groups for control of attack and prophylaxis against recurrent attacks. Emerging alternative medicine worldwide led investigators to evaluate the efficacy of cupping therapy plus SERKANGABIN syrup in treatment of migraine headache. Severity, duration and frequency of attacks of migraine headache evaluated in two groups during six months from presentation.

Details

Lead sponsor	Birjand University of Medical Sciences
Phase	Phase 4
Status	COMPLETED
Enrolment	391
Start date	2008-06
Completion	2011-10

Conditions

Migraine Headache

Interventions

cupping and serkangabin syrup
conventional migraine drug treatment

Primary outcomes

frequency of migraine attacks per week — 2 weeks after first presentation
endpoints evaluated in both study groups 2 weeks after first presentation and receiving treatment protocols

Countries

Iran